Total Payments
$28,820
2024 Payments
$17,657
Companies
38
Transactions
679
Medicare Patients
6,852
Medicare Billing
$1.3M
Payment Breakdown by Category
Other$16,800 (58.3%)
Food & Beverage$11,546 (40.1%)
Education$474.49 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Debt forgiveness | $16,800 | 2 | 58.3% |
| Food and Beverage | $11,546 | 669 | 40.1% |
| Education | $474.49 | 8 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ConvaTec Inc. | $16,858 | 4 | $0 (2024) |
| Gilead Sciences, Inc. | $1,759 | 110 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,360 | 95 | $0 (2024) |
| Astellas Pharma US Inc | $1,253 | 51 | $0 (2024) |
| ViiV Healthcare Company | $1,014 | 78 | $0 (2024) |
| ABBVIE INC. | $876.28 | 67 | $0 (2024) |
| Insmed, Inc. | $849.44 | 38 | $0 (2024) |
| TRIAD LIFE SCIENCES INC. | $760.02 | 15 | $0 (2022) |
| CIPLA USA INC. | $495.43 | 1 | $0 (2019) |
| Allergan, Inc. | $472.42 | 41 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17,657 | 50 | ConvaTec Inc. ($16,800) |
| 2023 | $1,460 | 69 | Astellas Pharma US Inc ($319.92) |
| 2022 | $1,568 | 69 | TRIAD LIFE SCIENCES INC. ($595.63) |
| 2021 | $1,191 | 82 | ViiV Healthcare Company ($259.47) |
| 2020 | $1,386 | 89 | Insmed, Inc. ($263.23) |
| 2019 | $3,112 | 176 | CIPLA USA INC. ($495.43) |
| 2018 | $1,531 | 96 | Merck Sharp & Dohme Corporation ($344.33) |
| 2017 | $916.31 | 48 | Astellas Pharma US Inc ($198.63) |
All Payment Transactions
679 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/13/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY | Food and Beverage | In-kind items and services | $21.16 | General |
| Category: VACCINES | ||||||
| 12/05/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO, AVYCAZ | Food and Beverage | In-kind items and services | $2.31 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/02/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: Respiratory | ||||||
| 11/26/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.86 | General |
| 11/11/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $14.72 | General |
| Category: Respiratory | ||||||
| 11/06/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $18.39 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.88 | General |
| 10/22/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $19.03 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/17/2024 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Food and Beverage | In-kind items and services | $21.63 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/16/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $16.12 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.06 | General |
| 09/09/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $22.54 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.24 | General |
| 08/27/2024 | ABBVIE INC. | DALVANCE (Drug), AVYCAZ, TEFLARO | Food and Beverage | In-kind items and services | $5.03 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/21/2024 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/20/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/15/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: VACCINES | ||||||
| 08/06/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/25/2024 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Food and Beverage | In-kind items and services | $15.85 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/24/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $21.76 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/23/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: Infections and Infectious Diseases | ||||||
| 07/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.16 | General |
| 07/09/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/03/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: VACCINES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 1,604 | 3,768 | $604,913 | $244,001 |
| 2022 | 8 | 804 | 2,395 | $486,474 | $184,939 |
| 2021 | 13 | 918 | 2,550 | $599,607 | $239,648 |
| 2020 | 32 | 3,526 | 8,835 | $1.4M | $620,324 |
Total Patients
6,852
Total Services
17,548
Medicare Billing
$1.3M
Procedure Codes
71
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 285 | 1,155 | $231,000 | $102,036 | 44.2% |
| 97597 | Removal of tissue from wound, 20.0 sq cm or less | Office | 2023 | 140 | 587 | $96,855 | $40,851 | 42.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 246 | 263 | $102,570 | $33,509 | 32.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 168 | 411 | $57,540 | $24,172 | 42.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 140 | 194 | $39,770 | $18,020 | 45.3% |
| 29581 | Application of vein wound compression bandages on lower leg, ankle, and foot | Office | 2023 | 26 | 64 | $15,510 | $5,107 | 32.9% |
| 97598 | Removal of tissue from wound, each additional 20.0 sq cm | Office | 2023 | 26 | 121 | $12,100 | $3,609 | 29.8% |
| 97140 | Therapy procedure using manual technique, each 15 minutes | Office | 2023 | 51 | 183 | $10,980 | $3,604 | 32.8% |
| 97162 | Evaluation for physical therapy, typically 30 minutes | Office | 2023 | 44 | 45 | $9,000 | $3,274 | 36.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 30 | 32 | $4,480 | $2,124 | 47.4% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 87 | 145 | $5,220 | $1,490 | 28.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $3,465 | $1,344 | 38.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 13 | $3,445 | $1,175 | 34.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 83 | 144 | $4,752 | $1,096 | 23.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 67 | 94 | $1,880 | $789.60 | 42.0% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2023 | 86 | 144 | $3,168 | $731.52 | 23.1% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 18 | 19 | $1,748 | $689.94 | 39.5% |
| 85652 | Red blood cell sedimentation rate, to detect inflammation, automated | Office | 2023 | 83 | 143 | $1,430 | $378.95 | 26.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 269 | 1,447 | $289,400 | $110,477 | 38.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 247 | 278 | $108,420 | $40,673 | 37.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 178 | 488 | $68,320 | $25,953 | 38.0% |
| 97597 | Removal of tissue from wound, 20.0 sq cm or less | Office | 2022 | 60 | 84 | $13,860 | $5,845 | 42.2% |
| 97598 | Removal of tissue from wound, each additional 20.0 sq cm | Office | 2022 | 13 | 39 | $3,900 | $1,256 | 32.2% |
| 97140 | Therapy procedure using manual technique, each 15 minutes | Office | 2022 | 14 | 21 | $1,260 | $388.86 | 30.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 12 | 20 | $720.00 | $208.24 | 28.9% |
About Dr. Stephen Threlkeld, M.D
Dr. Stephen Threlkeld, M.D is a Infectious Disease healthcare provider based in Memphis, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1578530895.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Threlkeld, M.D has received a total of $28,820 in payments from pharmaceutical and medical device companies, with $17,657 received in 2024. These payments were reported across 679 transactions from 38 companies. The most common payment nature is "Debt forgiveness" ($16,800).
As a Medicare-enrolled provider, Threlkeld has provided services to 6,852 Medicare beneficiaries, totaling 17,548 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Memphis, TN
- Active Since 03/06/2006
- Last Updated 01/02/2019
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1578530895
Products in Payments
- INNOVAMATRIX AC (Device) $17,396
- AVYCAZ (Drug) $922.88
- Arikayce (Drug) $753.25
- Cresemba (Drug) $620.86
- DOVATO (Drug) $606.78
- ZEMDRI (PLAZOMICIN) (Drug) $495.43
- ISENTRESS (Drug) $449.23
- XERAVA (Drug) $301.53
- DIFICID (Drug) $290.35
- DALVANCE (Drug) $286.56
- ZERBAXA (Drug) $270.14
- EGRIFTA (Drug) $236.26
- CRESEMBA (Drug) $231.48
- Xerava (Drug) $201.79
- PIFELTRO (Drug) $186.93
- CUVITRU (Biological) $174.02
- InnovaMatrix AC (Device) $164.39
- JULUCA (Drug) $157.35
- PREZCOBIX (Drug) $151.67
- NEOX (Medical Supply) $138.23
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Memphis
Dr. Michael Gelfand, Md, MD
Infectious Disease — Payments: $847,459
Infectious Disease $847,459
Dr. Kerry Cleveland, Md, MD
Infectious Disease — Payments: $679,099
Infectious Disease $679,099
Imad Omer, M.d, M.D
Infectious Disease — Payments: $22,171
Infectious Disease $22,171
Margarita Lamothe, M.d, M.D
Infectious Disease — Payments: $13,658
Infectious Disease $13,658
Dr. James Dale, Md, MD
Infectious Disease — Payments: $8,250
Infectious Disease $8,250
Michael Threlkeld, M.d, M.D
Infectious Disease — Payments: $4,437
Infectious Disease $4,437